Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tandem Diabetes Care's Beginning Cash Position for the quarter that ended in Jun. 2026 was MXN3,129 Mil.
Tandem Diabetes Care's quarterly Beginning Cash Position
declined
from Dec. 2025 (MXN1,656 Mil) to Mar. 2026 (MXN1,634 Mil) but then
increased
from Mar. 2026 (MXN1,634 Mil) to Jun. 2026 (MXN3,129 Mil).
Tandem Diabetes Care's annual Beginning Cash Position
declined
from Dec. 2023 (MXN2,928 Mil) to Dec. 2024 (MXN1,228 Mil) but then
increased
from Dec. 2024 (MXN1,228 Mil) to Dec. 2025 (MXN1,247 Mil).
Tandem Diabetes Care Beginning Cash Position Related Terms
Tandem Diabetes Care Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Beginning Cash Position Chart
What does a Beginning Cash Position of MXN3,129 Mil mean?
Tandem Diabetes Care (MEX:TNDM) has a Beginning Cash Position of MXN3,129 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Beginning Cash Position too high?
Tandem Diabetes Care's current Beginning Cash Position is MXN3,129 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Beginning Cash Position compare to AVNS and IRMD?
Tandem Diabetes Care's Beginning Cash Position of MXN3,129 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Beginning Cash Position is MXN3,129 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Tandem Diabetes Care (MEX:TNDM) has a current Beginning Cash Position of MXN3,129 Mil. The stock's GF Value™ is MXN1,190.26, compared to a current price of MXN745.00 — trading 37.4% below its estimated fair value. The current Beginning Cash Position is MXN3,129 Mil. Tandem Diabetes Care's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Tandem Diabetes Care (MEX:TNDM), the current Beginning Cash Position is MXN3,129 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (MEX:TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of MXN745.00 is trading 37.4% below its estimated GF Value™ of MXN1,190.26.
Key valuation signals for MEX:TNDM:
Beginning Cash Position: MXN3,129 Mil
GF Value™: MXN1,190.26 vs. price of MXN745.00 (37.4% below fair value)
No single metric tells the full story. See the MEX:TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
66GF Score
Get the complete analysis for MEX:TNDM
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TNDM has been successfully added to your 
